Chris Roth is the Vice President of Research at Abilita Therapeutics and has been with the company for nine years. Like Mauro, Chris acquired extensive experience in membrane protein engineering, production, and structure determination during his Ph.D. and postdoctoral work at The Scripps Research Institute where he was part of the team that solved some of the first high-resolution GPCR crystal structures and an inventor of key GPCR engineering technologies that continue to be used throughout the field. Chris left Scripps to join Receptos as one of the first members of the scientific team at Receptos and worked with the team to move GPCR structure-based approaches from an academic pursuit to real-world drug discovery.
